# EDGAR Filing Document

**Accession Number:** 0001325879
**File Stem:** 0001193125-23-002493
**Filing Date:** 2023-1
**Character Count:** 7300
**Document Hash:** de9a02b40fd5b7c840a09ef7fd5bab9f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-002493.hdr.sgml**: 20230105

**ACCESSION NUMBER**: 0001193125-23-002493

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230105

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20230105

**DATE AS OF CHANGE**: 20230105

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AVEO PHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0001325879
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 043581650
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-34655
- **FILM NUMBER:** 23512248

**BUSINESS ADDRESS:**
- **STREET 1:** 30 WINTER STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02108
- **BUSINESS PHONE:** 857-400-0101

**MAIL ADDRESS:**
- **STREET 1:** 30 WINTER STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02108

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AVEO PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20050503

?xml version="1.0" encoding="utf-8" ? 8-K

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

------

### FORM 8-K

------

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): January 5, 2023

------

## AVEO Pharmaceuticals, Inc.

#### (Exact Name of Registrant as Specified in its Charter)

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-34655** | **04-3581650** |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **30 Winter Street** |  |
| **Boston, Massachusetts** | **02108** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

#### Registrant's telephone number, including area code: (857) 400-0101

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common Stock, $0.001 par value | AVEO | Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.07.** | **Submission of Matters to a Vote of Security Holders.**  |

---

On January 5, 2023, AVEO Pharmaceuticals, Inc. (the "Company") held a special meeting of the stockholders of the Company (the "Special Meeting"). At the Special Meeting, the stockholders of the Company voted on the proposals set forth below, which were set forth in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 25, 2022, as supplemented on December 23, 2022. The final voting results for each proposal are set forth below. As of the close of business on November 18, 2022, the record date of the Special Meeting, there were 34,763,127 shares of common stock of the Company, par value $0.001 per share ("Company Common Stock"), outstanding, each of which was entitled to one vote on each proposal at the Special Meeting. At the Special Meeting, a total of 21,241,190 shares of Company Common Stock, representing approximately 61.1% of the outstanding shares of Company Common Stock entitled to vote, were present in person or represented by proxy, constituting a quorum to conduct business.

**Proposal No. 1 – The Merger Proposal**: To consider and vote on a proposal to adopt the Agreement and Plan of Merger, dated as of October 18, 2022, among LG Chem, Ltd., a corporation organized and existing under the laws of the Republic of Korea ("LG Chem"), Acacia Acquisition Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of LG Chem ("Merger Sub"), and the Company, pursuant to which Merger Sub will be merged with and into the Company, with the Company surviving the merger as an indirect wholly owned subsidiary of LG Chem (the "Merger," and such proposal, the "Merger Proposal")

The Merger Proposal was approved by the requisite vote of the Company's stockholders.

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 20092601 | 1124415 | 24174 |  |

---

**Proposal No. 2 – The Merger Compensation Proposal**: To consider and vote on a proposal to approve, on a non-binding, advisory basis, certain compensation that will or may be paid or become payable to the Company's named executive officers that is based on or otherwise relates to the Merger (the "Merger Compensation Proposal").

The Merger Compensation Proposal was approved by the requisite vote of the Company's stockholders.

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 18587382 | 2582409 | 71399 |  |

---

**Proposal No. 3 – The Adjournment Proposal**: To consider and vote on a proposal to approve the adjournment of the special meeting to a later date or dates if necessary to solicit additional proxies if there are insufficient votes to approve the Merger Proposal at the time of the Special Meeting (the "Adjournment Proposal")

The Adjournment Proposal was approved by the requisite vote of the Company's stockholders. However, adjournment of the Special Meeting was deemed not necessary because there was a quorum present and there were sufficient proxies at the time of the Special Meeting to approve the Merger Proposal.

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 19725209 | 1482467 | 33514 |  |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **AVEO Pharmaceuticals, Inc.** | **AVEO Pharmaceuticals, Inc.** |
| Date: January 5, 2023 | By: | /s/ Michael Bailey |
|  |  | Michael Bailey |
|  |  | President and Chief Executive Officer |

---